Replimune Group, Inc.
NASDAQ:REPLBiotechnology
+$0.19 today
- Market cap
- $1.88B
- Beta
- 0.91
- P/E (TTM)
- -3.0
- EPS (TTM)
- -$3.42
Volume 2.13M
Average 7.51M
REPL Effect of Forex Changes
Change in reported cash caused by exchange-rate movements on foreign-currency balances.
Replimune Group, Inc.NASDAQ: REPL
Effect of Forex Changes · Q3 FY2026 · quarter ended Dec 2025
Effect of forex changes turns positive
Q3 FY2026 effect of forex changes was $1.04M, compared with -$151K a year earlier. Trailing-twelve-month effect of forex changes was $1.5M. Over 3 fiscal years it compounded at -27.2% a year.
Context
- Effect of forex changes increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly effect of forex changes holds near $1.04M or moves back toward the trailing-twelve-month quarterly average of $375.5K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Effect of Forex Changes history
USD · from the cash flow
- Latest · FY2025
- 315K USD
- Year-over-year change
- +466.3%
- 4-year CAGR
- -18.7%
| Period | Period end | Effect of Forex Changes | YoY change |
|---|---|---|---|
| FY2025 | 2025-03-31 | 315K | +466.3% |
| FY2024 | 2024-03-31 | (86K) | +21.1% |
| FY2023 | 2023-03-31 | (109K) | -113.3% |
| FY2022 | 2022-03-31 | 818K | +13.5% |
| FY2021 | 2021-03-31 | 721K | — |
Effect of Forex Changes vs competitors
How REPL compares with its peers on the latest reported figures
- REPL's LTM Dec 2025 effect of forex changes of $1.5M is the 2nd largest of the 11 companies compared; the peer median is $0.
- Its year-over-year change of +713.1% is the highest of 5, against a peer median of +7.6%.
- Over three fiscal years its annual growth of -27.2% compares with a peer median of -57.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Dec 2025 | $83.14M | — | — | 114.3% | |
| LTM Dec 2025 | $1.5M | +713.1% | -27.2% | — | |
| LTM Sep 2026 | $562K | +191.4% | — | 0.1% | |
| LTM Sep 2026 | $299K | -10066.7% | -62.5% | 0.2% | |
| LTM Jun 2024 | $153.11K | — | -57.5% | 18.8% | |
| LTM Mar 2026 | $18K | +115.0% | +35.7% | 0.0% | |
| LTM Mar 2026 | $2K | -99.9% | — | 6.5% | |
| LTM Aug 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding REPL) | $0 | +7.6% | -57.5% | 0.1% | |
Competitors are the stored peer set for REPL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Mar 2021 | FY2022 Mar 2022 | FY2023 Mar 2023 | FY2024 Mar 2024 | FY2025 Mar 2025 |
|---|---|---|---|---|---|
| Net Income | (80.87M) | (118.04M) | (174.28M) | (215.79M) | (247.3M) |
| Depreciation & Amortization | 1.71M | 2.15M | 2.45M | 2.66M | 3.5M |
| Deferred Income Tax | 0 | 0 | 38K | 0 | 0 |
| Stock-Based Compensation | 11.79M | 24.25M | 28.13M | 34.13M | 35.04M |
| Change in Working Capital | 3.51M | 7.24M | 15.12M | 5.48M | 24.08M |
| Accounts Receivables | 325K | (247K) | (61K) | (1.92M) | 1.3M |
| Inventory | 0 | 247K | 61K | 0 | 0 |
| Accounts Payables | (1.03M) | 1.12M | 1.98M | (2.79M) | 9.94M |
| Other Working Capital | 4.22M | 6.12M | 13.14M | 10.19M | 12.84M |
| Other Non-Cash Items | 2.47M | 2.22M | 494K | (11.94M) | (7.58M) |
| Operating Cash Flow | (61.39M) | (82.18M) | (128.05M) | (185.47M) | (192.25M) |
| Capital Expenditures | (2.39M) | (2.34M) | (2.27M) | (5.66M) | (6.69M) |
| Acquisitions (Net) | 0 | (530) | 140.23K | 0 | 0 |
| Purchases of Investments | (392.43M) | (255.72M) | (583.41M) | (489.52M) | (403.59M) |
| Sales of Investments | 206.05M | 256.25M | 443.18M | 592.38M | 386.48M |
| Other Investing Activities | 0 | 530 | (140.23K) | 0 | 0 |
| Investing Cash Flow | (188.78M) | (1.81M) | (142.5M) | 97.2M | (23.8M) |
| Debt Repayment | (10.15M) | (264K) | 27.79M | 14.52M | (599K) |
| Common Stock Issued | 286.11M | 6.86M | 187.29M | 1.76M | 155.73M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 96.5M | 0 | 96.22M | 0 | 97.27M |
| Financing Cash Flow | 372.46M | 6.6M | 311.3M | 16.28M | 252.4M |
| Effect of Forex Changes | 721K | 818K | (109K) | (86K) | 315K |
| Net Change in Cash | 123.02M | (76.57M) | 40.64M | (72.07M) | 36.67M |
| Free Cash Flow | (63.78M) | (84.52M) | (130.32M) | (191.13M) | (198.94M) |
Replimune Group, Inc.
NASDAQ:REPL
Intrinsic Alpha fair value
Locked
Current Price
$19.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.